Drug Trial Radar · NCT01336634
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Last checked: Nov 20, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Aug 5, 2011
Primary completion
Oct 1, 2015
Study completion Jan 7, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects with BRAF mutant advanced non-small cell lung cancer. Central confirmation testing for the BRAF V600E mutation was performed and a sufficient number of subjects were enrolled with the intent of having at least 125 centrally confirmed subjects among the three cohorts.
Conditions
- Cancer
Interventions
DabrafenibDrug
Dabrafenib study treatment was provided as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)
TrametinibDrug
Trametinib study treatment was provided as 0.5 mg and 2 mg tablets. Each tablet contained 0.5 mg or 2 mg of trametinib parent (present as the dimethyl sulfoxide solvate)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months
Locations
50 sites in 11 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Orange, California
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Ann Arbor, Michigan
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Lebanon, New Hampshire
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Madison, Wisconsin
Novartis Investigative Site
Caen, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Frankfurt am Main, Germany
Novartis Investigative Site
Großhansdorf, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Moers, Germany
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Orbassano, Italy
Novartis Investigative Site
Osaka, Japan
Novartis Investigative Site
Tokyo, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Groningen, Netherlands
Novartis Investigative Site
Oslo, Norway
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Barcelona, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.